4种治疗脑梗死药物的成本-效果分析

目的对三七总苷、巴曲酶、尿激酶、奥扎格雷等4种药物治疗急性脑梗死进行成本 效果分析。方法将110例脑梗死患者分为A、B、C、D 4组，分别应用三七总苷、巴曲酶、尿激酶、奥扎格雷等4种药物治疗。运用药物经济学比较其成本 效果。 结果4种方案成本分别为587.72，2 498.401，4 060.00和2 839.20元。有效率分别为61.54%，92.86%，96.30%和93.10%。在方案A的基础上每再获得1个单位效果，方案B、C、D所需追加的成本依次为61.01，99.89和71.34元。结论采用巴曲酶治疗急性脑梗死为最佳方案。

Cost-effectiveness Analysis of Panax Notoginoside, Batroxobin, Urokinase and Ozagrel in Treatment of Cerebral Infarction

Objective To discuss the economic effects of panax notoginoside, batroxobin, urokinase and ozagrel in the treatment of cerebral infarction. Methods One hundred and ten cases of cerebral infarction were collected and divided into four groups treated with the above-mentioned 4 drugs respectively. Data were evaluated using the pharmacoeconomic costeffectiveness analysis. Results The costs of four groups were 587.72, 2498.40, 4060.00 and 2 839.20 yuans respectively. The effective rates of four groups were 61.54%, 92.86%, 96.30% and 93.10%, respectively. Compared with group A, group B, C and D costed 61.01, 99.89, ancl 71.34 yuans respectively for further increasing 1% effective rate. Conclusion Among the four groups, B group is the best one. So the optimal program is the application of batroxobin to treat cerebral infarction.